Hair Relaxer MDL Bellwether Pool Cut From Ten Cases to Five With General Causation Still Undecided

Judge Mary M. Rowland cut the hair relaxer MDL bellwether pool from ten cases to five on Thursday 17 September 2026, halving the set of test cases that will determine what roughly 12,129 pending federal claims are worth. The order matters far beyond the five women whose cases survived, because it was accompanied by rulings narrowing what economic damages the bellwether plaintiffs may put before a jury, and because it was entered while the single motion capable of ending the entire Multidistrict Litigation (MDL) — the defendants' joint challenge to the plaintiffs' General Causation experts under Federal Rule of Evidence 702 — remains undecided.

The striking thing about the hair relaxer MDL bellwether pool being reduced to five is that Rowland built the ten-case pool herself, earlier this year, for the express purpose of avoiding a five-case pool. In setting the larger group she warned that "preparing only five cases for trial runs the risk of these cases resolving short of trial or being subject to a dispositive motion and, thus, not being available to serve as representative bellwether cases." Five months on, the court has accepted exactly that risk. Reading the two decisions together tells practitioners more about where MDL 3060 is heading than any case count does.

What did the court decide in the hair relaxer MDL this week?

The court reduced the bellwether trial pool by half and fixed the boundaries of the damages case. Litigation trackers monitoring the docket report that on Thursday 17 September 2026 Judge Rowland narrowed the working bellwether pool in In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060, from the ten cases she had personally selected down to five. The docket text itself is not mirrored in any publicly accessible repository, and the five plaintiffs have not been identified in any source that can be corroborated, so anyone advising on a specific case should confirm the order from the docket in the Northern District of Illinois rather than from any summary, including this one.

Alongside the narrowing, the court resolved a set of disputes over the shape of the damages presentation. Four of the bellwether plaintiffs may pursue out-of-pocket medical expenses; three may pursue lost wages. Each must disclose the amounts claimed, and the information supporting them, by the court's deadlines. The court further indicated that claims for future medical expenses and for lost earning capacity require qualified expert support, while plaintiffs remain free to describe their own pain and suffering from the stand.

Those rulings look administrative. They are not. In a Mass Tort where no case has yet reached a jury and no Settlement Matrix exists, the first verdicts set the reference points that every later negotiation is measured against, and the composition of a verdict — how much is economic, how much is non-economic, whether Punitive Damages are reached — is what makes a number portable. A $5 million verdict built mostly on documented economic loss tells a defendant something very different from a $5 million verdict built almost entirely on pain and suffering. By restricting economic damages to the plaintiffs who can document them and requiring expert proof for forward-looking losses, the court has made the coming verdicts cleaner and, from the defense side, more predictable.

Why did Judge Rowland cut the hair relaxer bellwether pool from ten to five?

No published reasoning is available, and the honest answer is that the court has not explained itself on any record that can be read from outside the docket. What can be reconstructed is the trajectory, and the trajectory is unusually legible.

The selection history in MDL 3060 has been a steady transfer of control from the parties to the bench. The litigation was centralized before Judge Rowland by the Judicial Panel on Multidistrict Litigation (JPML) on 6 February 2023. A 32-case discovery pool was worked up, with fact discovery on that pool closing in March 2026. The parties were then supposed to trade picks under an alternating-selection protocol, with nominations due in early April 2026. Dissatisfied with what the party-driven process produced, Rowland scrapped the alternating picks and chose all ten trial-pool cases herself from the 32.

Her exclusions from that selection tell you what she wanted a Bellwether Trial in this litigation to look like. She left out cases naming only one or two defendants, cases in which the plaintiff had a second cancer diagnosis, a plaintiff with a parallel talc claim, and cases complicated by memory or mental health issues that would compete for the jury's attention with the questions actually being tested. The pool was confined to uterine, endometrial and ovarian cancer claims; fibroid and hysterectomy claims are being pursued primarily through state-court programs. What she was building was a set of clean, multi-defendant, single-diagnosis cases in which the jury's attention would fall on the product and the science rather than on the plaintiff.

Against that, the reduction to five reads as one of three things, and practitioners should hold all three:

• Trial-readiness triage. Five cases worked up to the standard Rowland has demanded is a heavy lift for both sides, and a court that intends to actually try cases in 2027 may prefer five fully prepared records to ten half-prepared ones.
• Attrition already suffered. Some of the ten may have resolved, been dismissed, or developed the very problems the exclusion criteria were designed to screen out. A pool that has shed cases is not the same as a pool that has been cut.
• A signal about the Rule 702 ruling. A court that expected to exclude the plaintiffs' general causation experts, and thereby end the litigation, would have little reason to spend its own and the parties' resources refining a trial pool at all. Narrowing to a working five is, weakly, the behavior of a court preparing to try cases.

The first reading is the most probable and the third is the most consequential. None of them is confirmed, and all of them are more useful than the flat statement, repeated across the intake pages currently ranking for this story, that the pool "was narrowed."

The attrition arithmetic behind a five-case bellwether pool

Rowland's earlier warning was not rhetorical. It described a failure mode that has recurred across large product MDLs: a bellwether pool is selected, individual cases settle on confidential terms or fall to case-specific summary judgment, and the court arrives at its trial date with nothing representative left to try. The hedge against that failure is redundancy, and redundancy is precisely what this week's order removed.

The exposure is easy to quantify. Case-specific Daubert Challenge and summary judgment motions are due in November 2026 on the public schedule. Assume, conservatively, that each of the five cases carries a 20% probability of being knocked out on Specific Causation, product identification or limitations grounds, and a further 20% probability of individual settlement before trial.

Pool size entering dispositive motions	Expected cases surviving to trial (at 36% attrition per case)	Probability the pool empties entirely
Ten cases	6.4	Effectively nil
Five cases	3.2	~0.6%
Three cases	1.9	~4.7%
Two cases	1.3	~13%

The illustration is not a prediction; the per-case attrition rate is an assumption, not a figure from the docket. What it shows is the structural point Rowland herself made. A ten-case pool is robust to ordinary attrition. A five-case pool is robust to ordinary attrition only if the attrition stays ordinary. The risk is not that the court ends up with zero cases — that remains unlikely — but that it ends up with one or two, and that the survivors are the unrepresentative ones, because the cases most likely to settle quietly are the strongest plaintiff cases and the cases most likely to fall on summary judgment are the weakest. Bellwether Trial outcomes derive their settlement-forcing power from being representative. A pool that has been filtered twice, once by the court's selection criteria and once by survivorship, is a narrower instrument than the ten-case pool was designed to be.

There is a counter-argument, and it is the defense side's. Ten cases tried seriatim is a multi-year project; five is a schedule a court can actually keep. In an MDL that has been pending since February 2023 without a single verdict, a smaller pool that produces two or three real jury results in 2027 is worth more to the settlement dynamics than a larger pool that produces none until 2029.

What is the general causation Daubert motion in the hair relaxer MDL?

It is the defendants' joint motion under Federal Rule of Evidence 702 to exclude the plaintiffs' expert testimony that chemical hair relaxers are capable of causing uterine, endometrial and ovarian cancer at all. It was filed on 5 May 2026, became fully briefed on 16 June 2026, and has not been decided. It is the most consequential undecided question in the litigation by a wide margin, and everything described in this article is provisional until it is resolved.

General Causation asks whether the agent can cause the disease in the general population; Specific Causation asks whether it did cause this plaintiff's disease. In a chemical-exposure MDL the first question is litigated once, on a common record, and the answer binds the inventory. If the plaintiffs' general causation experts are excluded, summary judgment across the federal docket follows as a matter of course and the bellwether pool — five cases or ten — becomes irrelevant. If they are admitted, the defendants' remaining paths are case-specific: product identification, exposure duration, competing risk factors, and the Statute of Limitations.

The epidemiological record the motion contests is narrower than the volume of filings suggests. The claims trace to a cluster of observational studies associating frequent use of chemical straightening products with elevated rates of hormone-sensitive reproductive cancers, and to the presence of phthalates, parabens and other endocrine-active constituents in the products. The defense position is the familiar one in this posture: association is not causation, the cohort findings do not survive adjustment, dose-response is not established, and the experts' reasoning runs from the conclusion backwards. Judge Rowland held a Science Day on 8 January 2026 with state-court judges in attendance — a signal that the court understood from the start that its evidentiary rulings would be read well beyond its own courtroom.

Practitioners tracking comparable dockets will recognize the pattern. The same Rule 702 gate is the pending fulcrum in the Depo-Provera and Ozempic MDLs, and in each the court's decision to reserve rather than rule from the bench has left a large inventory in suspension.

How many bellwether cases are left in the hair relaxer MDL, and what is the schedule?

Five, drawn from a ten-case trial pool that Rowland selected from a 32-case discovery pool, itself drawn from an inventory that stood at 12,129 pending actions in the JPML's report dated 1 September 2026. The public schedule, and the points at which it is inconsistent, are set out below.

Date	Event	Status
6 February 2023	JPML centralizes the hair relaxer litigation as MDL No. 3060 before Judge Mary M. Rowland, N.D. Ill.	Completed
3 March 2023	Leadership appointments made for the plaintiffs' committees	Completed
November 2023	Court dismisses four fraud-based claims; the bulk of the complaints survive the motions to dismiss	Completed
December 2025	Discovery stay entered protecting the Second Wave defendants	Completed
8 January 2026	Science Day held, with state-court judges attending	Completed
March 2026	Fact and general causation expert discovery closes on the 32-case bellwether pool	Completed
Early April 2026	Parties' bellwether nominations due; court scraps the alternating-picks protocol	Completed
5 May 2026	Defendants file joint Rule 702 motion to exclude plaintiffs' general causation experts	Filed
16 June 2026	Rule 702 motion fully briefed	Undecided
27 July 2026	Discovery stay lifted as to the Second Wave defendants	Completed
1 September 2026	JPML reports 12,129 actions pending; MDL 3060 is the fourth-largest MDL in the federal system	Reported
17 September 2026	Bellwether pool cut from ten cases to five; economic damages rulings entered	This week
29 September 2026	Outstanding interrogatory answers and document production responses due from the Second Wave defendants under Case Management Order No. 24	Upcoming
16 November 2026	Case-specific Daubert and summary judgment motions due (see the conflict noted below)	Upcoming
16 December 2026	Dispositive motions due on the alternative published schedule	Upcoming
Into February 2027	Dispositive and Daubert briefing completes	Upcoming
2027	First bellwether trials broadly expected; no trial date can be verified from a public docket entry	Expected
15 July 2027	General discovery against the Second Wave defendants closes under CMO No. 24	Fixed

Two inconsistencies in the public record deserve flagging, because they are reproduced uncritically across the pages currently ranking for this subject. First, sources split on the November and December dates: several state that case-specific Daubert and summary judgment motions are due 16 November 2026, while others describe 16 November as the close of expert discovery with dispositive motions following on 16 December 2026. Both versions cannot be right, and the difference is a month of work for anyone preparing those filings. Second, several intake-oriented pages now assert a first trial "in January," without identifying a docket entry or an order. No January trial date is corroborated by anything retrievable, and the same pages elsewhere describe first trials as "expected in 2027." Treat the January figure as unverified.

Case Management Order No. 24 and the Second Wave defendants

While the trial pool was being halved, the discovery half of the litigation was expanding. Magistrate Judge Beth W. Jantz entered Case Management Order No. 24 keeping general discovery against the Second Wave defendants open through 15 July 2027, with outstanding interrogatory answers and document production responses due on 29 September 2026.

The Second Wave defendants — the group reported to include Advanced Beauty Systems, Bronner Bros., Dudley Beauty, John Paul Mitchell Systems, Murray's Worldwide and Wella — were added to the litigation after the original defendant group and had been shielded by a discovery stay entered in December 2025. Judge Rowland lifted that stay on 27 July 2026, having concluded that the settlement discussions then under way did not justify a further pause.

Set the two dates side by side and the shape of the docket becomes clear. General discovery against one group of defendants runs until 15 July 2027. First trials against the original defendant group are expected during 2027. Those tracks are not synchronized, and they are not meant to be. What the court has built is a two-speed MDL: a trial track carrying five cases against the manufacturers whose products dominate the Product Identification evidence — L'Oréal USA and SoftSheen-Carson, Revlon, Strength of Nature, and the Namaste and Dabur entities, across brands including Dark & Lovely, Optimum, Mizani, Creme of Nature, Just for Me, Motions, African Pride, TCB and ORS Olive Oil — and a discovery track still building the record against a second tier of manufacturers who will not see a bellwether verdict before their own discovery closes.

For the Second Wave group that is a meaningful advantage. They will watch the first verdicts, and the general causation ruling, from a position where their own exposure has not yet been tested and their documents are still being produced. For claimants' counsel it is a caution: a plaintiff whose Product Identification rests principally on a Second Wave brand is not on the trial track that the September order accelerated, whatever the headline settlement pressure in the MDL as a whole.

When will the first hair relaxer trial take place?

No trial date is verifiable from a public docket entry. The realistic window is 2027, and the reasoning is arithmetic rather than speculation: case-specific Daubert and summary judgment briefing does not complete until early 2027 on either version of the published schedule, and the court will not try a bellwether case before it has ruled on the motions directed at that case. Add the pending general causation ruling, which logically precedes case-specific work, and a first trial in the first half of 2027 requires the court to decide Rule 702 promptly and the parties to hold every remaining deadline.

That is why the reduction to five is best read as a trial-readiness measure. A court with a 2027 target and a schedule this compressed is choosing depth over redundancy. It is also why the claim of a January trial, circulating without a citation, should not be relayed to clients. Intake pages have an incentive to compress litigation timelines; dockets do not move because marketing says they will.

Does the bellwether cut affect pending hair relaxer claims?

Directly, no. Indirectly, it affects all of them.

No filed case is dismissed, revived, revalued or re-tiered by the narrowing of a trial pool. A claimant whose case sits in the MDL inventory is in the same procedural position today as on Wednesday: the case remains subject to the court's Plaintiff Fact Sheet (PFS) obligations, remains bound by whatever the court decides on general causation, and remains untried.

Indirectly the effects are real and run in both directions:

• Fewer data points. Five bellwethers can produce at most five verdicts. Every settlement negotiation in this litigation will be conducted against a thinner evidentiary base than the ten-case pool promised, and thin samples produce wide bargaining ranges. A single defense verdict in a three-verdict series carries far more weight than it would in a seven-verdict series.
• Higher variance per outcome. The smaller the pool, the more each individual result moves the market. That cuts both ways: an eight-figure plaintiff verdict in a five-case pool would be the most valuable asset the plaintiffs' side has acquired in three and a half years of this litigation.
• A shorter runway to information. Against those costs, a smaller pool is likely to yield verdicts sooner. For a claimant who filed in 2023 and has had no valuation signal since, earlier information has genuine value.
• A compressed damages template. The economic damages rulings entered this week apply to bellwether plaintiffs, but they preview what documentary proof the court expects. Claimants' counsel who have not collected wage records, medical billing and treatment documentation should read those rulings as the standard the court will apply when the inventory moves.

Is there a hair relaxer settlement yet, and how much are hair relaxer cases worth?

There is no Global Settlement, no settlement program, no Settlement Matrix, and no payments have been made to any hair relaxer claimant by any defendant. Any figure presented as an "average hair relaxer settlement amount" is a projection produced by a firm or a lead vendor, not a term agreed by a party, and there is no negotiated tier structure from which such a number could be derived.

That is the single most important correction this article makes to the material currently ranking for this subject. Several of the top-ranking pages carry per-case dollar ranges, and some are careful to label them as estimates while others are not. The verifiable position is simpler: manufacturers have issued no payouts; settlement discussions have taken place and were, as recently as July 2026, not substantial enough in the court's view to justify continuing the Second Wave discovery stay; and the litigation has never tested a claim in front of a jury.

What will set values, when values are set, is a sequence that has not begun. The Rule 702 ruling establishes whether there is a litigation at all. The bellwether verdicts — now at most five — establish the range. A Settlement Matrix, if one is ever negotiated, will then sort claimants by cancer type, exposure duration and frequency, age at diagnosis, treatment intensity and documented economic loss, in roughly that order. Until the first of those steps is complete, valuation is guesswork dressed in decimal places.

Can new hair relaxer claims still be filed after the bellwether cut?

Yes. Nothing in the 17 September order closed the docket, imposed a filing deadline, or created a Census Registry or Lone Pine Order screening obligation of the kind that has narrowed intake in other mature mass torts. MDL 3060 remains an open filing market — on one tracker's assessment, the largest open intake market in the United States since the AFFF docket closed its filing window in September 2025 — and the inventory has continued to grow through 2026, from 11,195 pending actions in February to 11,526 on 1 May, 11,877 on 1 July, 11,779 on 3 August and 12,129 on 1 September.

The limits on a new claim come from substantive law rather than from the MDL's own machinery. Three constraints do the work. The first is the Statute of Limitations in the state whose law governs, which in a latent-disease case ordinarily runs from diagnosis or from the point at which the claimant knew or should have known of the connection between the product and the injury under the applicable Discovery Rule; the widely reported epidemiology that generated this litigation was published in late 2022, and defendants have argued that publicity dates the clock. The second is Product Identification: a claimant who cannot name specific brands and an approximate usage history faces a proof problem that no amount of general causation evidence repairs, and the bellwether selection criteria show how much the court values multi-defendant exposure records. The third is diagnosis. The federal trial track is confined to uterine, endometrial and ovarian cancer; fibroid and hysterectomy claims exist in volume but are being pursued mainly through state-court programs and are not what the five remaining bellwethers will test.

A claimant filing today should also understand what they are filing into. The case will be subject to the court's Plaintiff Fact Sheet (PFS) regime, will sit behind an undecided general causation motion, and will not be individually worked up for years. That is the ordinary condition of a claim in a 12,000-case MDL, but it is worth stating plainly in a market where intake advertising implies a faster path than the docket supports.

How MDL 3060's five-case pool compares

Bellwether pools are sized against the inventory they are meant to resolve, and by that measure MDL 3060's is now very small.

Litigation	Approximate pending federal inventory	Working bellwether pool	Verdicts to date
Hair relaxer (MDL 3060, N.D. Ill.)	12,129 (1 September 2026)	5	None
Talc (MDL 2738, D.N.J.)	~69,000	Superseded by an announced aggregate settlement	Multiple state-court verdicts
Uber passenger assault (MDL 3084, N.D. Cal.)	Several thousand	Sequential bellwethers under way	Plaintiff verdicts in the first federal bellwethers
Bard implanted port catheter (MDL 3081, D. Ariz.)	~4,000	Sequential bellwethers under way	$40m plaintiff verdict, September 2026

The comparison is not an argument that five is wrong. It is an argument that five is thin for an inventory of this size, and that the ratio of test cases to claims — roughly one bellwether for every 2,400 pending actions — leaves each verdict carrying an unusual load.

What it means for defense counsel, claimants' counsel, funders and state-court filers

For defense counsel. The economic damages rulings are the immediate win and should be worked accordingly: the disclosure obligations attached to them are an opportunity to test documentation before trial, and the requirement of expert support for future medicals and lost earning capacity constrains the most elastic component of the damages case. The strategic question is the Second Wave timetable. A client in that group now has a genuine structural advantage — verdicts against the first tier will land before its own discovery closes on 15 July 2027 — and the value of that advantage declines the moment it is traded away in an early resolution.

For claimants' counsel. Two deadlines dominate the next ninety days: the Second Wave production deadline of 29 September 2026, and the case-specific dispositive and Daubert deadline in November or December 2026, which is now materially more dangerous because the pool has no redundancy. A case-specific loss that would have been absorbed by a ten-case pool now removes a fifth of the trial programme. Inventory holders should also treat the damages rulings as a documentation standard and audit their files against it now rather than when a Settlement Matrix forces the issue.

For litigation funders and portfolio buyers. Third-Party Litigation Funding positions in this docket are exposed to a single binary event that has been fully briefed since June and could issue any day. The bellwether reduction slightly shortens the expected time to a verdict signal while widening the distribution of that signal. Anything priced against an "average settlement" figure is priced against a number that does not exist; a position in MDL 3060 today is a position on Rule 702, not on a matrix.

For state-court filers. A federal Rule 702 ruling does not bind a state court applying its own evidentiary standard, and the hair relaxer inventory includes substantial state-court filings, particularly the fibroid and hysterectomy claims that the federal bellwether criteria excluded. The presence of state-court judges at the January 2026 Science Day signals coordination, not preclusion. For a claimant with a viable state forum and a timely claim, the federal bellwether contraction changes very little.

Frequently asked questions

What did the court decide in the hair relaxer MDL this week?

On Thursday 17 September 2026 Judge Mary M. Rowland reduced the hair relaxer MDL bellwether pool from ten cases to five in MDL No. 3060 in the Northern District of Illinois, and entered companion rulings allowing four bellwether plaintiffs to pursue out-of-pocket medical expenses and three to pursue lost wages, with expert support required for future medical costs and lost earning capacity.

How many hair relaxer lawsuits are pending?

The JPML's report dated 1 September 2026 records 12,129 actions pending in MDL No. 3060, making it the fourth-largest MDL in the federal system. Total filings since centralization exceed 16,000, and state-court claims are additional to the federal figure.

Has a hair relaxer case ever gone to trial?

No. No hair relaxer claim in MDL 3060 has been tried to verdict since the litigation was centralized on 6 February 2023. First bellwether trials are broadly expected in 2027, and no trial date can be verified from a public docket entry.

What happens if the court excludes the plaintiffs' general causation experts?

Summary judgment across the federal inventory would follow as a matter of course, and the bellwether pool would become moot. The defendants' joint Rule 702 motion has been fully briefed since 16 June 2026 and remains undecided, which makes it the single largest source of risk on either side of this litigation.

Does the smaller bellwether pool mean the hair relaxer cases are settling?

There is no evidence for that reading. There is no global settlement and no payments have been made. The court lifted the Second Wave discovery stay on 27 July 2026 after concluding that the settlement discussions then under way did not justify keeping it in place, which points away from an imminent resolution rather than toward one.

Which defendants are still in the hair relaxer litigation?

The principal manufacturer defendants include L'Oréal USA and SoftSheen-Carson, Revlon, Strength of Nature, and the Namaste and Dabur entities, across brands including Dark & Lovely, Optimum, Mizani, Creme of Nature, Just for Me, Motions, African Pride, TCB and ORS Olive Oil. A separate Second Wave group — reported to include Advanced Beauty Systems, Bronner Bros., Dudley Beauty, John Paul Mitchell Systems, Murray's Worldwide and Wella — remains in general discovery through 15 July 2027 under Case Management Order No. 24.